Forum Discussion

NWhite1's avatar
NWhite1
Member
7 hours ago

Zoladex 3 monthly available but not PBS covered for women

I wanted to share something I recently learned as it might help ease the burden of regular monthly injections.

I recently learned that the goserelin injections many of us have monthly are actually available in a  3 monthly dose (10.8mg). I was a really hopeful thinking this could significantly reduce the stress, time and cost that comes with needing to have an injection every 4 weeks.

However, my Med Onc informed me that in Australia, the PBS doesn't subsidise the 3 monthly dose for women, although it does for men (prostate cancer). The reasoning given that there's `insufficient evidence of reliable suppression of serum oestradiol' in women. 
What doesn't make sense is that there is evidence suggesting otherwise. Recent research indicates that the 3 monthly dose is non-inferior to the monthly dose for pre-menopausal women with breast cancer in terms of ovarian suppression.

For me, the monthly injections come with a real burden:

  • financially - GP visits and medication add up every month
  • time wise - frequent GP appointments and pharmacy trips take time out of the week.
  • physically and emotionally - injection itself is painful, it's a large slow release implant into the abdominal subcutaneous tissue.

The main alternative - surgical removal of the ovaries is obviously much more invasive and comes with it's own risks and long term consequences.

Given that the 3 monthly option is already in use, clinically tested and could ease the burden for many of us, I would really like to see equal PBS access for women. 

I'm curious, has anyone else looked into this and how to go about taking action?

2 Replies

  • ThanksChristina_BCNA​ that sounds promising. I wonder how they are progressing as it seems so unreasonable. FYI The recent study that the 3 month is non inferior to the monthly dose was published just last year. 

  • Christina_BCNA's avatar
    Christina_BCNA
    Community Manager

    Thank you for sharing this NWhite1​ -  it’s a really important issue, and many will relate to the burdens you’ve outlined. Our Policy & Advocacy team is aware of PBS issues and are active in this space, I've passed this on to them to look into further so your experience can help inform their ongoing work :)